Keep me updated about investment opportunities in the area of oncology and life sciences.
Jounce Therapeutics initiates Phase 2 portion of ICONIC study of JTX-2011 in patients with advanced solid tumors.
Tracon awarded 'Most Innovative Trial Design' for Phase 3 TAPPAS clinical trial of TRC105 in angiosarcoma at 2017 Clinical and Research Excellence Awards
Kura Oncology presents preclinical data demonstrating significant anti-tumor activity of KO-947 and KO-539
Blueprint Medicines announces closing of public offering and full exercise of option to purchase additional shares of common stock
Kura Oncology to present preclinical data for development compounds at AACR Annual Meeting 2017
Jounce Therapeutics to present at AACR annual meeting on JTX-2011 cancer immunotherapy program
Sunesis Pharmaceuticals announces submission of responses to the EMA day 180 list of outstanding issues for marketing authorization application for Vosaroxin
Blueprint Medicines announces enrollment of first patient in phase 1 clinical trial for BLU-667
Your eMail have been successfully registered.Close